FIELD: biotechnology.
SUBSTANCE: antibody options are proposed binding to a programmed cell death 1 (hereinafter – PD-1) protein. Nucleic acid, an expression vector and a host cell used in a method for producing an anti-PD-1 antibody, according to the invention, are also proposed. In addition, the invention relates to a pharmaceutical composition and the use of antibodies, according to the invention, to produce a drug. Antibodies are used in methods for the treatment of mammals. For instance, antibodies can be used for treating cancer, strengthening an immune response, increasing the activation of a T-cell, reducing the size of tumor or increasing the level of IFNγ and IL-2 cytokines in a mammal.
EFFECT: obtaining antibodies to PD-1 for the treatment of mammals.
97 cl, 9 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
